Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing

Clinical Pharmacology and Therapeutics

Volumn 98, Issue 1, 2015, Pages 19-24

  Birdwell, K A ^a   Decker, B ^b   Barbarino, J M ^c   Peterson, J F ^a,d   Stein, C M ^a,e   Sadee, W ^f   Wang, D ^f   Vinks, A A ^g,h   He, Y ⁱ   Swen, J J ^j   Leeder, J S ^k   Van Schaik, R H N ^l   Thummel, K E ^m   Klein, T E ^c   Caudle, K E ⁿ   MacPhee, I A M ^o  

^a VANDERBILT UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c STANFORD UNIVERSITY   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^g CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^h UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

ⁱ CENTRAL SOUTH UNIVERSITY   (China)

^j LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^k CHILDREN S MERCY HOSPITAL   (United States)

^l ERASMUS MEDICAL CENTER   (Netherlands)

^m UNIVERSITY OF WASHINGTON   (United States)

ⁿ ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^o ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; INTERLEUKIN 2; TACROLIMUS; TRANSCRIPTION FACTOR NFAT; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CLINICAL PRACTICE; DRUG BLOOD LEVEL; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HUMAN; PHARMACOGENETICS; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEPHOSPHORYLATION; T LYMPHOCYTE ACTIVATION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; ORGAN TRANSPLANTATION;

CYTOCHROME P-450 CYP3A; GENETIC TESTING; GENOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; TACROLIMUS;

EID: 84962207669     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.113     Document Type: Article

References (40)

1. Finta C, & Zaphiropoulos P.G. The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene. 260, 13-23 (2000).
2. Kuehl P, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391 (2001).
3. van Schaik R.H, van der Heiden I.P, van den Anker J.N, & Lindemans J. CYP3A5 variant allele frequencies in Dutch caucasians. Clin. Chem. 48, 1668-1671 (2002).
4. Thompson E.E, Kuttab-Boulos H, Witonsky D, Yang L, Roe B.A, & Di Rienzo A. CYP3A variation, and the evolution of salt-sensitivity variants. Am. J. Hum. Genet. 75, 1059-1069 (2004).
5. Bowman L.J, & Brennan D.C. The role of tacrolimus in renal transplantation. Expert Opin. Pharmacother. 9, 635-643 (2008).
6. Kershner R.P, & Fitzsimmons W.E. Relationship of FK506 whole blood concentrations, and efficacy, and toxicity after liver, and kidney transplantation. Transplantation. 62, 920-926 (1996).
7. Wallemacq P, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther. Drug Monit. 31, 139-152 (2009).
8. Undre N.A, & Stevenson P.J. European Tacrolimus Heart Study Group. Pharmacokinetics of tacrolimus in heart transplantation. Transplant. Proc. 34, 1836-1838 (2002).
9. Braun F, et al. Therapeutic drug monitoring of tacrolimus early after liver transplantation. Transplant. Proc. 34, 1538-1539 (2002).
10. Ekberg H, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N. Engl. J. Med. 357, 2562-2575 (2007).
11. Bouamar R, et al. Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials. Am. J. Transplant. 13, 1253-1261 (2013).
12. Haufroid V, et al. The effect of CYP3A5, and MDR1 (ABCB1) polymorphisms on cyclosporine, and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics. 14, 147-154 (2004).
13. Santoro A, et al. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients. Pharmacogenomics. 12, 1293-1303 (2011).
14. Zheng S, et al. Measurement, and compartmental modeling of the effect of CYP3A5 gene variation on systemic, and intrarenal tacrolimus disposition. Clin. Pharmacol. Ther. 92, 737-745 (2012).
15. Morales J.M, Andres A, Rengel M, & Rodicio J.L. Influence of cyclosporin, tacrolimus, and rapamycin on renal function, and arterial hypertension after renal transplantation. Nephrol. Dial. Transplant. 16 (suppl. 1), 121-124 (2001).
16. Nankivell B.J, Borrows R.J, Fung C.L, O?Connell P.J, Allen R.D, & Chapman J.R. The natural history of chronic allograft nephropathy. N. Engl. J. Med. 349, 2326-2333 (2003).
17. Thervet E, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin. Pharmacol. Ther. 87, 721-726 (2010).
18. Rojas L, et al. Effect of CYP3A5.3 on kidney transplant recipients treated with tacrolimus: a systematic review, and meta-Analysis of observational studies. Pharmacogenomics J. 15, 38-48 (2015).
19. Fukudo M, et al. Impact of MDR1, and CYP3A5 on the oral clearance of tacrolimus, and tacrolimus-related renal dysfunction in adult livingdonor liver transplant patients. Pharmacogenet. Genomics. 18, 413-423 (2008).
20. Li D, Zhu J.Y, Gao J, Wang X, Lou Y.Q, & Zhang G.L. Polymorphisms of tumor necrosis factor-Alpha, interleukin-10, cytochrome P450 3A5, and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus. Clin. Chim. Acta. 383, 133-139 (2007).
21. Muraki Y, et al. Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics, and infectious complications after living-donor liver transplantation for Japanese adult recipients. Ann. Transplant. 16, 55-62 (2011).
22. Wei-lin W, et al. Tacrolimus dose requirement in relation to donor and recipient ABCB1, and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl. 12, 775-780 (2006).
23. Yu S, et al. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. Transplantation. 81, 46-51 (2006).
24. Ji E, Choi L, Suh K.S, Cho J.Y, Han N, & Oh J.M. Combinational effect of intestinal, and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation. Transplantation. 94, 866-872 (2012).
25. Zheng H, et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5, and MDR1 gene polymorphisms. Am. J. Transplant. 3, 477-483 (2003).
26. Gijsen V, et al. Age, and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients. J. Heart Lung Transplant. 30, 1352-1359 (2011).
27. Guy-Viterbo V, et al. Influence of donor-recipient CYP3A4/5 genotypes, age, and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach. Pharmacogenomics. 15, 1207-1221 (2014).
28. Ferraresso M, et al. Influence of the CYP3A5 genotype on tacrolimus pharmacokinetics, and pharmacodynamics in young kidney transplant recipients. Pediatr. Transplant. 11, 296-300 (2007).
29. Zhao W, et al. Population pharmacokinetics, and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin. Pharmacol. Ther. 86, 609-618 (2009).
30. Ferraris J.R, et al. Influence of CYP3A5 polymorphism on tacrolimus maintenance doses, and serum levels after renal transplantation: age dependency, and pharmacological interaction with steroids. Pediatr. Transplant. 15, 525-532 (2011).
31. de Wildt S.N, et al. The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation. Eur. J. Clin. Pharmacol. 67, 1231-1241 (2011).
32. García-Roca P, et al. CYP3A5 polymorphism in Mexican renal transplant recipients, and its association with tacrolimus dosing. Arch. Med. Res. 43, 283-287 (2012).
33. Lalan S, et al. Effect of CYP3A5 genotype, steroids, and azoles on tacrolimus in a pediatric renal transplant population. Pediatr. Nephrol. 29, 2039-2049 (2014).
34. Kausman J.Y, Patel B, & Marks S.D. Standard dosing of tacrolimus leads to overexposure in pediatric renal transplantation recipients. Pediatr. Transplant. 12, 329-335 (2008).
35. Kuypers D.R, de Jonge H, Naesens M, & Vanrenterghem Y. Effects of CYP3A5, and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus, and fluconazole in renal allograft recipients. Pharmacogenet. Genomics. 18, 861-868 (2008).
36. Chandel N, Aggarwal P.K, Minz M, Sakhuja V, Kohli K.K, & Jha V. CYP3A5 1/ 3 genotype influences the blood concentration of tacrolimus in response to metabolic inhibition by ketoconazole. Pharmacogenet. Genomics. 19, 458-463 (2009).
37. van Gelder T. Drug interactions with tacrolimus. Drug Saf. 25, 707-712 (2002).
38. Staatz C.E, & Tett S.E. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin. Pharmacokinet. 43, 623-653 (2004).
39. Moore J, et al. Donor ABCB1 variant associates with increased risk for kidney allograft failure. J. Am. Soc. Nephrol. 23, 1891-1899 (2012).
40. Macphee I.A, et al. Tacrolimus pharmacogenetics: the CYP3A5 1 allele predicts low dose-normalized tacrolimus blood concentrations in whites, and South Asians. Transplantation. 79, 499-502 (2005).